244 related articles for article (PubMed ID: 9129786)
21. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
22. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.
Ohmori T; Koyama T; Inoue T; Matsubara S; Yamashita I
Biol Psychiatry; 1993 May; 33(10):687-93. PubMed ID: 8102551
[TBL] [Abstract][Full Text] [Related]
23. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
[TBL] [Abstract][Full Text] [Related]
24. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
[TBL] [Abstract][Full Text] [Related]
26. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
[TBL] [Abstract][Full Text] [Related]
27. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics.
Olbrich R; Schanz H
Pharmacopsychiatry; 1988 Nov; 21(6):389-90. PubMed ID: 2907647
[No Abstract] [Full Text] [Related]
28. Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients.
Valevski A; Modai I; Zbarski E; Zemishlany Z; Weizman A
Clin Neuropharmacol; 1998; 21(6):355-7. PubMed ID: 9844793
[TBL] [Abstract][Full Text] [Related]
29. [Clinical aspects and follow-up of dopamine-induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms].
Heinz A; Przuntek H; Winterer G; Pietzcker A
Nervenarzt; 1995 Sep; 66(9):662-9. PubMed ID: 7477603
[TBL] [Abstract][Full Text] [Related]
30. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
Ceballos-Baumann AO
MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
[TBL] [Abstract][Full Text] [Related]
31. An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia.
Nakajima S; Uchida H; Suzuki T; Tomita M; Tsunoda K; Kitta M; Takeuchi H; Nomura K; Watanabe K; Kashima H
J Clin Psychopharmacol; 2007 Aug; 27(4):401-3. PubMed ID: 17632230
[No Abstract] [Full Text] [Related]
32. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
Koshikawa H; Suzuki E; Kanba S; Nibuya M; Ishizuki T; Kohno H; Kinoshita N; Shintani F; Yagi G; Nakaki T
Yakubutsu Seishin Kodo; 1991 Feb; 11(1):79-81. PubMed ID: 1679276
[No Abstract] [Full Text] [Related]
33. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
Volavka J; Douyon R; Convit A; Czobor P; Cooper TB
Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388
[No Abstract] [Full Text] [Related]
34. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
35. Treatment of extrapyramidal side effects with terguride.
Filip V; Marsálek M; Hálková E; Karen P
Psychiatry Res; 1992 Jan; 41(1):9-16. PubMed ID: 1348584
[TBL] [Abstract][Full Text] [Related]
36. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.
Davidson M; Davis KL
Arch Gen Psychiatry; 1988 Jun; 45(6):561-3. PubMed ID: 3377642
[TBL] [Abstract][Full Text] [Related]
37. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
38. Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics.
Freudenreich O; McEvoy JP
J Clin Psychiatry; 1995 Apr; 56(4):173. PubMed ID: 7713860
[No Abstract] [Full Text] [Related]
39. Beyond the therapeutic window: a case presentation.
Schulz SC; Butterfield L; Garicano M; Narasimhachari N; Friedel RO
J Clin Psychiatry; 1984 May; 45(5):223-5. PubMed ID: 6725212
[TBL] [Abstract][Full Text] [Related]
40. Correlation between plasma concentrations of chlorpromazine and clinical response.
Rivera-Calimlim L; Gift T; Nasrallah HA; Wyatt RJ; Lasagna L
Commun Psychopharmacol; 1978; 2(3):215-22. PubMed ID: 699536
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
